For decades, there has been no cure and few treatment options.

The companies anticipate finalising the acquisition in the third quarter of 2026.

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...

For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.

Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

Muscular dystrophy (MD) is a group of genetic diseases that cause your muscles to progressively weaken and degenerate. There are several types of MD, each with its own symptoms, but they all involve ...

London: Edgewise Therapeutics on Monday agreed to sell its muscular dystrophy drug and related business to Servier in a deal ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

Muscular dystrophy is a group of disorders that involve a progressive loss of muscle mass and consequent loss of strength. In general, the condition is caused by genetic variations that interfere with ...